Clinical Trials Logo
  1. Home
  2. Platelet Reactivity
  3. NCT00976196

Platelet Hyperreactivity Project — PHP  

Platelet Reactivity Clinical Trial

Official title:
Platelet Hyperreactivity Project: A System Biology Approach of High On-treatment Platelet Reactivity in Aspirin-treated Cardiovascular Patients

Clinical Trial Summary

The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients.

Clinical Trial Description

The PHP study aims to delineate gene products involved in high on-treatment platelet reactivity in aspirin-treated cardiovascular patients using a system biology approach that include proteomics analysis of selected platelet sub-fractions in patients displaying extreme phenotype.

Main objective:

- to characterize the proteome profile of platelet hyperreactivity in aspirin-treated cardiovascular patients

Secondary objectives:

- to characterize the platelet hyperreactivity phenotype in cardiovascular patients treated with aspirin

- to determine genetic polymorphisms associated with platelet hyperreactivity ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00976196
Study type Observational
Source University Hospital, Geneva
Contact
Status Completed
Phase N/A
Start date January 2009
Completion date January 2010
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02808039 - Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial N/A
Completed NCT01961856 - Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor. Phase 3
Recruiting NCT03525145 - Platelet Reactivity And Clinical ThrombotIC Events Study
Completed NCT01463150 - Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI) Phase 4
Completed NCT01463163 - Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI) Phase 4
Recruiting NCT03614832 - Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD Phase 4
Completed NCT01835353 - High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI) Phase 3
Completed NCT04001894 - Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease Phase 4
Recruiting NCT05773989 - Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy Phase 4
Completed NCT01511471 - Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis Phase 3
Completed NCT00827346 - Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty Phase 2/Phase 3
Recruiting NCT05367336 - Platelet Reactivity With Fentanyl, Morphine, or no Narcotic Early Phase 1
Completed NCT03679091 - Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD. Phase 4
Recruiting NCT05657041 - Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease Phase 2/Phase 3